Propel Bio Management
Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PAGP, ACHV, PHAT, DCTH, CORT, and represent 41.65% of Propel Bio Management's stock portfolio.
- Added to shares of these 10 stocks: CORT (+$6.0M), VOR (+$5.6M), DCTH (+$5.1M), OBIO, FDMT, OCUL, UPB, AQST, EYPT, TRVI.
- Started 22 new stock positions in VOR, FDMT, EYPT, OBIO, EVMN, OVID, CORT, IMUX, PALI, ARTV. CNTB, ALDX, TRVI, Satellos Bioscience, NUVB, QURE, UPB, OCUL, MAZE, CHRS, CRVS, AQST.
- Reduced shares in these 10 stocks: NKTR, RGNX, IVA, VRDN, OCS, LENZ, CLDX, CMPS, AARD, KYTX.
- Sold out of its positions in AARD, LENZ, NKTR, RGNX.
- Propel Bio Management was a net buyer of stock by $53M.
- Propel Bio Management has $159M in assets under management (AUM), dropping by 35.46%.
- Central Index Key (CIK): 0001969764
Tip: Access up to 7 years of quarterly data
Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 38 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Plains Gp Hldgs Ltd Partnr Int A (PAGP) | 19.0 | $30M | 1.3M | 23.72 |
|
|
| Achieve Life Sciences (ACHV) | 7.2 | $11M | 3.8M | 3.00 |
|
|
| Phathom Pharmaceuticals (PHAT) | 5.9 | $9.4M | +13% | 841k | 11.12 |
|
| Delcath Sys Com New (DCTH) | 5.8 | $9.2M | +123% | 980k | 9.35 |
|
| Corcept Therapeutics Incorporated (CORT) | 3.8 | $6.0M | NEW | 148k | 40.74 |
|
| Abeona Therapeutics Com New (ABEO) | 3.8 | $6.0M | +60% | 1.3M | 4.52 |
|
| Vor Biopharma Com New (VOR) | 3.5 | $5.6M | NEW | 315k | 17.76 |
|
| Kyverna Therapeutics (KYTX) | 3.5 | $5.6M | -3% | 644k | 8.67 |
|
| Milestone Pharmaceuticals (MIST) | 3.2 | $5.1M | 4.1M | 1.23 |
|
|
| Celldex Therapeutics Com New (CLDX) | 2.6 | $4.1M | -14% | 131k | 31.48 |
|
| Compass Pathways Sponsored Ads (CMPS) | 2.6 | $4.1M | -13% | 742k | 5.55 |
|
| Miragen Therapeutics (VRDN) | 2.6 | $4.1M | -25% | 210k | 19.45 |
|
| Inventiva Sa Ads (IVA) | 2.5 | $4.0M | -27% | 725k | 5.51 |
|
| Sab Biotherapeutics Com New (SABS) | 2.4 | $3.9M | +55% | 1.0M | 3.84 |
|
| Health Sciences Acq Corp 2 (OBIO) | 2.4 | $3.8M | NEW | 897k | 4.27 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.3 | $3.6M | NEW | 380k | 9.41 |
|
| Oculis Holding Ordinary Shares (OCS) | 2.1 | $3.3M | -29% | 122k | 26.83 |
|
| Ocular Therapeutix (OCUL) | 2.0 | $3.2M | NEW | 382k | 8.44 |
|
| Upstream Bio (UPB) | 2.0 | $3.1M | NEW | 342k | 9.07 |
|
| Aquestive Therapeutics (AQST) | 1.9 | $3.0M | NEW | 711k | 4.15 |
|
| Eyepoint Com New (EYPT) | 1.8 | $2.8M | NEW | 216k | 12.92 |
|
| Trevi Therapeutics (TRVI) | 1.7 | $2.6M | NEW | 224k | 11.83 |
|
| Zevra Therapeutics Com New (ZVRA) | 1.7 | $2.6M | +343% | 282k | 9.35 |
|
| Immunic (IMUX) | 1.7 | $2.6M | NEW | 2.3M | 1.12 |
|
| Coherus Biosciences (CHRS) | 1.5 | $2.4M | NEW | 1.4M | 1.70 |
|
| Ovid Therapeutics (OVID) | 1.3 | $2.0M | NEW | 922k | 2.21 |
|
| Palisade Bio (PALI) | 1.3 | $2.0M | NEW | 1.1M | 1.79 |
|
| Kalaris Therapeutics (KLRS) | 1.1 | $1.7M | +603% | 296k | 5.82 |
|
| Uniqure Nv SHS (QURE) | 1.1 | $1.7M | NEW | 105k | 16.35 |
|
| Athira Pharma (LONA) | 0.9 | $1.5M | 149k | 10.02 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.9 | $1.4M | NEW | 329k | 4.29 |
|
| Maze Therapeatics (MAZE) | 0.8 | $1.3M | NEW | 44k | 29.85 |
|
| Evommune Com Shs (EVMN) | 0.8 | $1.3M | NEW | 56k | 22.99 |
|
| Corvus Pharmaceuticals (CRVS) | 0.8 | $1.3M | NEW | 86k | 14.58 |
|
| Aldeyra Therapeutics (ALDX) | 0.8 | $1.2M | NEW | 731k | 1.69 |
|
| Artiva Biotherapeutics (ARTV) | 0.6 | $950k | NEW | 146k | 6.49 |
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.3 | $554k | NEW | 210k | 2.64 |
|
| Satellos Bioscience | 0.0 | $57k | NEW | 10k | 5.63 |
|
Past Filings by Propel Bio Management
SEC 13F filings are viewable for Propel Bio Management going back to 2023
- Propel Bio Management 2026 Q1 filed May 14, 2026
- Propel Bio Management 2025 Q4 filed Feb. 11, 2026
- Propel Bio Management 2025 Q3 filed Nov. 12, 2025
- Propel Bio Management 2025 Q2 filed Aug. 13, 2025
- Propel Bio Management 2025 Q1 filed May 15, 2025
- Propel Bio Management 2024 Q4 filed Feb. 14, 2025
- Propel Bio Management 2024 Q3 filed Nov. 13, 2024
- Propel Bio Management 2024 Q2 filed Aug. 12, 2024
- Propel Bio Management 2024 Q1 filed May 13, 2024
- Propel Bio Management 2023 Q4 filed Feb. 14, 2024